Chromatin remodeling and cancer, part I: covalent histone modifications

Trends in Molecular Medicine

Volumn 13, Issue 9, 2007, Pages 363-372

  Wang, Gang G ^a   Allis, C David ^a   Chi, Ping ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DNA; HISTONE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 8; HISTONE H2B; HISTONE H3; LYSINE; SERINE;

ACETYLATION; APOPTOSIS; CANCER; CARCINOGENESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOMAL INSTABILITY; CHROMOSOME CONDENSATION; CHROMOSOME SEGREGATION; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DNA REPLICATION; EPIGENETICS; GENETIC TRANSCRIPTION; HUMAN; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN VARIANT; REVIEW;

ANIMALS; CHROMATIN; HISTONES; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 34548526743     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2007.07.003     Document Type: Review

References (77)

1. Goldberg A.D., et al. Epigenetics: a landscape takes shape. Cell 128 (2007) 635-638
2. Robertson K.D. DNA methylation and human disease. Nat. Rev. Genet. 6 (2005) 597-610
3. Baylin S.B., and Ohm J.E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat. Rev. Cancer 6 (2006) 107-116
4. Moss T.J., and Wallrath L.L. Connections between epigenetic gene silencing and human disease. Mutat. Res. 618 (2007) 163-174
5. Jones P.A., and Baylin S.B. The Epigenomics of Cancer. Cell 128 (2007) 683-692
6. Kouzarides T. Chromatin modifications and their function. Cell 128 (2007) 693-705
7. Shogren-Knaak M., et al. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 311 (2006) 844-847
8. Shogren-Knaak M., and Peterson C.L. Switching on chromatin: mechanistic role of histone H4-K16 acetylation. Cell Cycle 5 (2006) 1361-1365
9. Jenuwein T., and Allis C.D. Translating the histone code. Science 293 (2001) 1074-1080
10. Shi Y., and Whetstine J.R. Dynamic regulation of histone lysine methylation by demethylases. Mol. Cell 25 (2007) 1-14
11. Taverna S.D., et al. Yng1 PHD finger binding to H3 trimethylated at K4 promotes NuA3 HAT activity at K14 of H3 and transcription at a subset of targeted ORFs. Mol. Cell 24 (2006) 785-796
12. Pena P.V., et al. Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2. Nature 442 (2006) 100-103
13. Shi X., et al. ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression. Nature 442 (2006) 96-99
14. Fraga M.F., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37 (2005) 391-400
15. Seligson D.B., et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435 (2005) 1262-1266
16. Sparmann A., and van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 6 (2006) 846-856
17. Bracken A.P., et al. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 20 (2006) 1123-1136
18. Vire E., et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439 (2006) 871-874
19. Croonquist P.A., and Van Ness B. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 24 (2005) 6269-6280
20. Varambally S., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419 (2002) 624-629
21. Kleer C.G., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 11606-11611
22. Su I.H., et al. Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 121 (2005) 425-436
23. Haupt Y., et al. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell 65 (1991) 753-763
24. van Lohuizen M., et al. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 65 (1991) 737-752
25. Jacobs J.J., et al. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397 (1999) 164-168
26. Jacobs J.J., et al. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 13 (1999) 2678-2690
27. Lessard J., and Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423 (2003) 255-260
28. Pardal R., et al. Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer 3 (2003) 895-902
29. Grewal S.I., and Jia S. Heterochromatin revisited. Nat. Rev. Genet. 8 (2007) 35-46
30. Norwood L.E., et al. A requirement for dimerization of HP1Hsalpha in suppression of breast cancer invasion. J. Biol. Chem. 281 (2006) 18668-18676
31. Dillon S.C., et al. The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol. 6 (2005) 227
32. Peters A.H., et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 107 (2001) 323-337
33. Lachner M., et al. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 410 (2001) 116-120
34. Garcia-Cao M., et al. Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. Nat. Genet. 36 (2004) 94-99
35. Nielsen S.J., et al. Rb targets histone H3 methylation and HP1 to promoters. Nature 412 (2001) 561-565
36. Braig M., et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436 (2005) 660-665
37. Kim K.C., et al. Inactivation of a histone methyltransferase by mutations in human cancers. Cancer Res. 63 (2003) 7619-7623
38. Gibbons R.J. Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum. Mol. Genet. 14 (2005) R85-R92 Spec No 1
39. Steele-Perkins G., et al. Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily. Genes Dev. 15 (2001) 2250-2262
40. Yang Z.Q., et al. Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer Res. 60 (2000) 4735-4739
41. Ehrbrecht A., et al. Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. J. Pathol. 208 (2006) 554-563
42. Italiano A., et al. Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma: 9p23 neocentromere and 9p23-p24 amplification including JAK2 and JMJD2C. Cancer Genet. Cytogenet. 167 (2006) 122-130
43. Cloos P.A., et al. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 442 (2006) 307-311
44. Hess J.L. MLL: a histone methyltransferase disrupted in leukemia. Trends Mol. Med. 10 (2004) 500-507
45. Ernst P., et al. Definitive hematopoiesis requires the mixed-lineage leukemia gene. Dev. Cell 6 (2004) 437-443
46. Hamamoto R., et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat. Cell Biol. 6 (2004) 731-740
47. Shi X., and Gozani O. The fellowships of the INGs. J. Cell. Biochem. 96 (2005) 1127-1136
48. Garkavtsev I., et al. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 428 (2004) 328-332
49. Kichina J.V., et al. Targeted disruption of the mouse ing1 locus results in reduced body size, hypersensitivity to radiation and elevated incidence of lymphomas. Oncogene 25 (2006) 857-866
50. Rahman N. Mechanisms predisposing to childhood overgrowth and cancer. Curr. Opin. Genet. Dev. 15 (2005) 227-233
51. Wang G.G., et al. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat. Cell Biol. 7 (2007) 804-812
52. Kurotaki N., et al. Haploinsufficiency of NSD1 causes Sotos syndrome. Nat. Genet. 30 (2002) 365-366
53. Rayasam G.V., et al. NSD1 is essential for early post-implantation development and has a catalytically active SET domain. EMBO J. 22 (2003) 3153-3163
54. Feng Q., et al. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr. Biol. 12 (2002) 1052-1058
55. Okada Y., et al. hDOT1L links histone methylation to leukemogenesis. Cell 121 (2005) 167-178
56. Okada Y., et al. Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L. Nat. Cell Biol. 8 (2006) 1017-1024
57. Marks P., et al. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1 (2001) 194-202
58. Yang X.J. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res. 32 (2004) 959-976
59. Iyer N.G., et al. p300/CBP and cancer. Oncogene 23 (2004) 4225-4231
60. Bolden J.E., et al. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5 (2006) 769-784
61. Bereshchenko O.R., et al. Acetylation inactivates the transcriptional repressor BCL6. Nat. Genet. 32 (2002) 606-613
62. Zhu P., et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5 (2004) 455-463
63. Fernandez-Capetillo O., et al. H2AX: the histone guardian of the genome. DNA Repair (Amst.) 3 (2004) 959-967
64. Dery U., and Masson J.Y. Twists and turns in the function of DNA damage signaling and repair proteins by post-translational modifications. DNA Repair (Amst.) 6 (2007) 561-577
65. Stucki M., et al. MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell 123 (2005) 1213-1226
66. Bassing C.H., et al. Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell 114 (2003) 359-370
67. Celeste A., et al. H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell 114 (2003) 371-383
68. Kops G.J., et al. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat. Rev. Cancer 5 (2005) 773-785
69. Carter S.L., et al. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet. 38 (2006) 1043-1048
70. Weaver B.A., et al. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 11 (2007) 25-36
71. Fischle W., et al. Regulation of HP1-chromatin binding by histone H3 methylation and phosphorylation. Nature 438 (2005) 1116-1122
72. Hirota T., et al. Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin. Nature 438 (2005) 1176-1180
73. Terada Y. Aurora-B/AIM-1 regulates the dynamic behavior of HP1alpha at the G2-M transition. Mol. Biol. Cell 17 (2006) 3232-3241
74. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
75. Ahn S.H., et al. Sterile 20 kinase phosphorylates histone H2B at serine 10 during hydrogen peroxide-induced apoptosis in S. cerevisiae. Cell 120 (2005) 25-36
76. Cheung W.L., et al. Apoptotic phosphorylation of histone H2B is mediated by mammalian sterile twenty kinase. Cell 113 (2003) 507-517
77. Ahn S.H., et al. Histone H2B deacetylation at lysine 11 is required for yeast apoptosis induced by phosphorylation of H2B at serine 10. Mol. Cell 24 (2006) 211-220